Efficacy of serputinib/serpatinib (Ruitu) in the treatment of RET fusion-positive tumors

Selpercatinib, a drug targeting RET fusion gene mutations, has shown significant efficacy in the treatment of RET fusion-positive tumors. RET gene fusion is a mutation phenomenon that is common in various tumor types such as non-small cell lung cancer (NSCLC) and thyroid cancer. RET fusion gene mutations lead to the continued proliferation of cancer cells. By inhibiting the activity of RET kinase, Seputinib blocks the abnormal signaling pathways caused by this mutation, thereby inhibiting the proliferation of cancer cells and achieving good clinical results.

In the treatment of non-small cell lung cancer, the proportion of patients with RET fusion gene mutations is relatively low, but for these patients, seputinib is a revolutionary treatment option. Studies have shown that seputinib can significantly prolong the progression-free survival (PFS) of patients with RET fusion-positive NSCLC and effectively reduce the tumor burden. Compared with traditional chemotherapy, seputinib can not only target tumor cells more accurately, but also effectively reduce damage to normal cells, thereby reducing side effects. In addition, seputinib has relatively low drug resistance and can effectively control disease progression and bring longer survival to patients.

Septinib has also shown good efficacy in the treatment of thyroid cancer. RET fusion gene mutation is a common driver gene mutation in thyroid cancer, especially in differentiated thyroid cancer. For these patients, seputinib can effectively inhibit tumor growth and delay disease progression. Research data shows that seputinib can significantly improve the clinical response rate of patients with RET fusion-positive thyroid cancer, making it one of the first-choice drugs for the treatment of RET fusion-positive thyroid cancer.

In general, seputinib has a very significant therapeutic effect on patients with RET fusion-positive tumors, especially non-small cell lung cancer and thyroid cancer. It can accurately target RET gene mutations, inhibit the growth and proliferation of cancer cells, and significantly improve the quality of life and prognosis of patients.

Reference:https://en.wikipedia.org/wiki/Selpercatinib